In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.
Some of the best links we picked up around the internet
Verve Therapeutics demonstrates preclinical proof-of-concept with support from Beam Therapeutics
Multiple new deals and developments and new base editor data from Intellia Therapeutics
This week’s update looks at a Phase 1 clinical trial for a new meganuclease-edited CAR T-cell therapy for Non-Hodgkin lymphoma (NHL).